Methotrexate ELISA Kit (DEIA-XYZ209)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
urine, blood, oral fluid
Species Reactivity
Human
Intended Use
CD's Methotrexate ELISA kit is a qualitative one-step kit designed for use as a screening device for the detection of Methotrexate in human urine, blood or oral fluid. The kit was designed for screening purposes and is intended for forensic use only.
Sensitivity
Compound I-50 in EIA Buffer
Methotrexate 0.22 ng/mL
Aminopterin 0.66 ng/mL
Triamterene 29.7 ng/mL

Citations


Have you cited DEIA-XYZ209 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma

PEDIATRIC BLOOD & CANCER

Authors: Young, Elizabeth P.; Cheng, W. Susan; Bernhardt, Melanie B.; Wang, Lisa L.; Rainusso, Nino; Foster, Jennifer H.

High-dose methotrexate (HD-MTX; 12 g/m(2)) is part of standard therapy for pediatric osteosarcoma (OS). Risk factors associated with MTX toxicity in children with OS are not well defined. We investigated the association between peak MTX levels (four-hour) and delayed MTX clearance or treatment toxicity. Information was retrieved from electronic medical records of 33 OS patients treated with HD-MTX at Texas Children's Hospital from 2008 to 2015. We found that the four-hour MTX level did not contribute to toxicity or delayed MTX clearance. We demonstrated that certain demographic characteristics are associated with delayed clearance and increased toxicity.

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

RMD OPEN

Authors: den Braanker, Hannah; Wervers, Kim; Mus, Adriana M. C.; Bangoer, Priyanka S.; Davelaar, Nadine; Luime, Jolanda; Tchetverikov, Ilja; Hazes, J. M. W.; Vis, Marijn; Lubberts, Erik; Kok, Marc R.

Objectives Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describes the response to MTX monotherapy in newly diagnosed patients with PsA in usual care. Second, we compared clinical variables and cytokine profiles in patients responding and not responding to MTX monotherapy. Methods We used data collected in the Dutch southwest Early Psoriatic Arthritis cohoRt study to select patients with PsA with oligoarthritis or polyarthritis, and at least 1 year follow-up. We analysed disease activity at 6 months of patients who started MTX monotherapy and still used MTX monotherapy 1 year after diagnosis. Cytokine profiles were determined at baseline and after 3 and 6 months with a bead-based multi-immunoassay. Results We identified 219 patients of which 183 (84%) patients started MTX monotherapy within 6 months after diagnosis. 90 patients used MTX monotherapy throughout the first year of which 44 patients (24%) reached minimal disease activity(MDA) at 6 months, decreasing to 33 patients (18%) after 1 year. Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy. Conclusions Our results showed that only 18% of patients with PsA are in sustained MDA after 1 year of MTX monotherapy and non-responders more often had IL-23driven disease. Our results indicate the need for more treatto-target and personalised therapy strategies in PsA.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket